Taxane resistance in prostate cancer is mediated by decreased drug-target engagement
Ada Gjyrezi(Cornell University), Rupal S. Bhatt(Dana-Farber Cancer Institute)
Cited by 53
Related Papers
Early Actions of Anti–Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels
|American Journal Of Pathology|2017|37
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance
|Clinical Cancer Research|2021|32
A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).
|Journal of Clinical Oncology|2017|12
Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma
|Clinical Genitourinary Cancer|2018|8